Cargando…

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Rades, Dirk, Zwaan, Inga, Idel, Christian, Pries, Ralph, Bruchhage, Karl L., Hakim, Samer G., Yu, Nathan Y., Soror, Tamer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381843/
https://www.ncbi.nlm.nih.gov/pubmed/37511733
http://dx.doi.org/10.3390/jpm13071120
_version_ 1785080544289095680
author Rades, Dirk
Zwaan, Inga
Idel, Christian
Pries, Ralph
Bruchhage, Karl L.
Hakim, Samer G.
Yu, Nathan Y.
Soror, Tamer
author_facet Rades, Dirk
Zwaan, Inga
Idel, Christian
Pries, Ralph
Bruchhage, Karl L.
Hakim, Samer G.
Yu, Nathan Y.
Soror, Tamer
author_sort Rades, Dirk
collection PubMed
description Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned.
format Online
Article
Text
id pubmed-10381843
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103818432023-07-29 A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer Rades, Dirk Zwaan, Inga Idel, Christian Pries, Ralph Bruchhage, Karl L. Hakim, Samer G. Yu, Nathan Y. Soror, Tamer J Pers Med Article Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned. MDPI 2023-07-10 /pmc/articles/PMC10381843/ /pubmed/37511733 http://dx.doi.org/10.3390/jpm13071120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rades, Dirk
Zwaan, Inga
Idel, Christian
Pries, Ralph
Bruchhage, Karl L.
Hakim, Samer G.
Yu, Nathan Y.
Soror, Tamer
A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title_full A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title_fullStr A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title_full_unstemmed A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title_short A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
title_sort new prognostic instrument for predicting the probability of completion of cisplatin during chemoradiation for head and neck cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381843/
https://www.ncbi.nlm.nih.gov/pubmed/37511733
http://dx.doi.org/10.3390/jpm13071120
work_keys_str_mv AT radesdirk anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT zwaaninga anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT idelchristian anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT priesralph anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT bruchhagekarll anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT hakimsamerg anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT yunathany anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT sorortamer anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT radesdirk newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT zwaaninga newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT idelchristian newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT priesralph newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT bruchhagekarll newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT hakimsamerg newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT yunathany newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer
AT sorortamer newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer